Efficacy and Safety of NP-2007 on Skin Health

NCT07486414 | Completed

• 1 other identifier: NP2007_HPN
• Study Type: interventional
• Target: 84
• Locations: 1 country
• Sites: 1

Brief Summary

The objective of this study is to evaluate the efficacy and safety of Small-molecular-weight deer antler collagen (NP-2007) on skin health, including skin hydration, transepidermal water loss (TEWL), elasticity, and eye wrinkles.

Conditions

Skin Aging, Dry Skin

Outcome Measures

Primary Outcomes (6)

• Change from Baseline in Skin Hydration at 12 weeks

  Measured using Corneometer® CM 825. The unit of measure is arbitrary units (AU) ranging from 0 to 120. Higher scores indicate improved skin moisture.

  Baseline, 6 weeks, 12 weeks

• Change from Baseline in Transepidermal Water Loss (TEWL) at 12 Weeks

  Measured using Tewameter® TM 300. The unit of measure is g/m²/h. Lower values indicate improved skin barrier function.

  Baseline, 6 weeks, 12 weeks

• Change from Baseline in Skin Scaling at 12 Weeks

  Evaluated using D-Squame® and image analysis. Higher values indicate more scaling (worse), lower values indicate improvement.

  Baseline, 6 weeks, 12 weeks

• Change from Baseline in Skin Roughness at 12 Weeks

  Measured using Visiometer® SV 700. Assesses the texture of the skin surface. Lower values indicate smoother skin.

  Baseline, 6 weeks, 12 weeks

• Change from Baseline in Eye Wrinkles (Ra) at 12 Weeks

  Quantitative analysis of eye wrinkles (crow's feet) using Visiometer® SV 700. Ra represents the average roughness in millimeters (mm). Lower values indicate improved wrinkle depth.

  Baseline, 6 weeks, 12 weeks

• Change from Baseline in Skin Elasticity (R2) at 12 Weeks

  Measured using Cutometer® MPA 580. R2 represents gross elasticity (0 to 1 scale). Higher values indicate better skin elasticity.

  Baseline, 6 weeks, 12 weeks

Secondary Outcomes (2)

• Investigator's Visual Assessment Grade for Eye Wrinkles

  Clinical grading of eye wrinkle severity by a dermatologist. The grade is based on a visual scale from 0 to 9 (0 = None, 9 = Very Severe). Lower grades indicate clinical improvement in wrinkle severity.

• Participant Subjective Questionnaire Assessment for Skin Improvement

  Participants assess skin improvement and satisfaction through a self-report questionnaire using a 5-point Likert scale (1 = Very Dissatisfied, 5 = Very Satisfied). Higher scores indicate greater satisfaction with the product's efficacy.

Study Arms (2)

NP-2007

EXPERIMENTAL

500mg/day, once a day, take 2 tablets with water.

Dietary Supplement: NP-2007

Placebo

PLACEBO COMPARATOR

Take 2 tablets (matching NP-2007) once a day with water.

Dietary Supplement: Placebo

Interventions

NP-2007 DIETARY_SUPPLEMENT

500mg/day, once a day, take 2 tablets with water.

NP-2007

Placebo DIETARY_SUPPLEMENT

Take 2 tablets (matching NP-2007) once a day with water.

Placebo

Eligibility Criteria

• Age: 35 Years - 65 Years
• Gender Eligibility Details: Only female participants are included in this study as the evaluation of skin aging parameters (e.g., crow's feet wrinkles) was specifically targeted at the female population based on the study protocol.
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Healthy females between 35 and 65 years of age
• Subjects with dry skin (Skin capacitance ≤ 49 units measured by Corneometer® CM 825)
• Subjects with eye wrinkles (grade 3 or higher based on visual assessment scale)
• Subjects who voluntarily signed the informed consent form after receiving a full explanation of the study
• Subjects who are available for follow-up visits at scheduled times throughout the study period

You may not qualify if:

• \) Subjects with skin diseases (atopic dermatitis, psoriasis, etc.) in the test area
• \) Subjects who have used skin-related medications (steroids, etc.) within 1 month
• \) Subjects with a history of hypersensitivity to the test ingredients or severe food allergies
• \) Pregnant or lactating women, or those planning to become pregnant
• \) Subjects who have participated in other clinical trials within the past 3 months
• \) Any other conditions that the investigator deems unsuitable for participation

Sponsors & Collaborators

• Hanpoong Nature Pharm Co., Ltd.: lead

Study Sites (1)

Corederm Skin Research Center

Seoul, South Korea

Location

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: DOUBLE
• Who Masked: PARTICIPANT, INVESTIGATOR
• Purpose: PREVENTION
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: March 13, 2026
• First Posted: March 20, 2026
• Study Start: April 4, 2022
• Primary Completion: July 15, 2022
• Study Completion: September 30, 2022
• Last Updated: March 20, 2026

Record last verified: 2026-03

Locations

KR (1)